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Automated robust proton planning using dose-volume histogram based mimicking of the photon reference dose and reducing organ at risk dose optimization Running title: Automated robust proton planning
Summary (<75 words)
An automated approach to robust pencil beam scanning proton planning has been presented by first mimicking the dose-volume histograms of the photon dose and secondly reducing the dose to non-target tissues. This 'mimicking and reducing' algorithm was evaluated in head and neck cancer patients and successfully embedded into a framework to automatically select patients for proton therapy based on normal tissue complication probabilities.
Abstract (<300 words)
Patient selection for proton therapy is increasingly based on proton to photon plan comparisons. To improve efficient decision making, we developed a dose mimicking and reducing (DMR) algorithm to automatically generate a robust proton plan from a reference photon dose and target and organs at risk (OARs) delineations.
The DMR algorithm was evaluated in 40 head and neck cancer patients. The first step of the DMR algorithm comprises DVH-based mimicking of the photon dose distribution in the clinical target volumes and OARs. Target robustness is included by mimicking the nominal photon dose in 21 perturbed scenarios. The second step of the optimization aims to reduce the OAR doses while retaining the robust target coverage as achieved in the first step. We evaluated each DMR plan against the 'manually' robustly optimized reference proton plan in terms of plan robustness (voxel-wise minimum dose). Furthermore, the DMR plans were evaluated against the reference photon plan using normal tissue complication probability M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
(NTCP) models of xerostomia, dysphagia and tube feeding dependence. Consequently, ∆NTCPs were defined as the difference between the NTCPs of the photon and proton plans.
The dose distributions of the DMR and reference proton plans were very similar in terms of target robustness and OAR dose values. Regardless of proton planning technique (i.e. DMR or reference proton plan), the same treatment modality was selected in 80% (32/40) of cases based on the ∑∆NTCPs. In 15%
Introduction
Head and neck cancer (HNC) patients are often treated with radiotherapy with or without systemic treatment and/or surgery. Modern radiotherapy includes intensity modulated techniques using either photons or protons. The current standard radiation technique is intensity modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) aiming at highly conformal target coverage with sparing of non-target tissues. The physical properties of the proton beam (i.e., the Bragg peak) may even further improve dose conformity with less dose to organs at risk (OARs) [1, 2] . In particular, the relatively recent introduction of pencil beam scanning (PBS) technology, together with robust multi-field optimization (MFO), has shown the greatest promise in reducing non-target dose, especially in complex target regions such as HNC [3] . Due in part to these benefits, there has been a steep increase in the availability of PBS world-wide, through both new facilities as well as existing facilities upgrading to PBS from older technologies. Despite this however, the capacity for treating HNC cancer patients with proton therapy remains limited.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
In the Netherlands, patients selection for proton therapy in HNC is performed using the 'model-based approach', a national framework which outlines the criteria in which a significant clinical benefit can be expected relative to photon treatments [4, 5] . This approach uses normal tissue complication probability (NTCP) models to compare the expected radiation-induced side effects (such as grade 2 xerostomia, dysphagia and grade 3 tube feeding dependence) arising from both proton and photon therapy, based upon the dose distribution of the patient's treatment plan and clinically relevant prognostic factors. If the difference between NTCP values (∆NTCP) of the two plans is above a pre-defined threshold, the patient is eligible for proton therapy.
Cheng et al. developed a pipeline to automatically calculate the preferred treatment modality per patient based on dose, toxicity (i.e. NTCP models) and cost-effectiveness within minutes [6] . The time and resource intensive generation of photon and proton treatment plans for each patient were however not included in their analysis. This is a substantial departmental burden which would greatly benefit from automation.
Several approaches to (semi-) automated treatment planning have been presented in literature [7] [8] [9] [10] [11] [12] [13] .
Examples of automated planning tools include the use of knowledge-based planning using previously approved treatment plans of different patients [7, 8] and multicriteria optimization methods [9] [10] [11] [12] [13] . The second step of the optimization therefore aims to reduce the OAR dose as much as possible. The presented reducing OAR dose optimization aims to not deteriorate on target coverage as achieved during the first step, also accounting for plan robustness. The goal of this study was to determine whether this new DMR algorithm was able to generate a robustly optimized proton plan of equal or better 'quality' than the reference, dosimetrist-optimized proton plan. If so, the algorithm could be used within an automated workflow to determine the selection of HNC patients that would benefit from proton therapy the most.
Material and methods

Patients
Forty HNC patients that were prospectively registered at our institute between September 2014 and June 2016 and that were treated to the primary tumors and to the elective lymph nodal areas, at both sides of the neck, and that had weekly acquired repeat CT images available (as part of our quality assurance programme) were enrolled in this study. All patients were treated with curative intent using IMRT (n = 14) or VMAT (n = 26) with or without concomitant chemotherapy or cetuximab. Tumors were staged with TNM classifications of T1-4, N0-3, and M0-1 and originated in the nasopharynx (n = 4), glottic larynx (n = 6), hypopharynx (n = 5), oropharynx (tonsil: n = 7; base of tongue: n = 6 posterior wall: n = 1), supraglottic larynx (n = 7), oral cavity (n = 2), and other regions (n = 2).
All patients were treated with a simultaneous integrated boost technique comprising the following dose 
Reference proton plan (Pref)
For each patient, a robustly optimized PBS proton plan was created by one dosimetrist using MFO as implemented in RayStation (v4.99.0). Four beams were used, including two anterior oblique beams (gantry and couch angles: beam 1 approx. 50˚ and 340˚; beam 2 approx. 310˚ and 20˚) and two beams from posterior oblique direction (gantry and couch angles: beam 3 approx. 150˚ and 0˚; beam 4 approx.
200˚ and 0˚). To avoid any range uncertainties in the shoulder and neck region, only the anterior beams contributed to the caudal part of the target. Moreover, the beam directions were manually chosen such that dose to the parotids was avoided as much as possible. All beams used a 4.0 cm range shifter to allow for adequate coverage of superficial target volumes. The air gap between the range shifter and the patient was 
Pipeline model-based approach
The model-based approach has previously been introduced to select the preferred treatment modality for the individual patient, based on NTCP models [4] . The selection is based on ∆NTCP values as derived from e.g. a photon and a proton dose distribution and evaluated against predefined thresholds. If the preestablished ∆NTCP threshold is exceeded, the patient is referred for proton therapy, otherwise the patient receives photon radiotherapy. Figure 1 illustrates how ∆NTCP is derived using the DMR algorithm given a reference photon dose and corresponding decision criteria. The NTCP models as well as the thresholds for different grades of complication are shown in table 1. These NTCP models and thresholds have recently been established in the 'Dutch National Indication Protocol for Proton Therapy' [18] .
Dose mimicking
PBS proton treatment plans were automatically generated using an extended version of the original 'reducing OAR dose' algorithm as described by [15] . Our extension comprised of photon to robust proton dose mimicking and was implemented in a research version of RayStation (v5.99.0). The DMR algorithm consists of the following components, as illustrated in Figure 1: 1. The beam angles are selected.
2. The ROIs that are to be considered in the optimization are selected.
3. The reference dose is set to the dose distribution of the photon plan to be mimicked.
4.
A robust dose mimicking optimization is performed using 21 perturbed scenarios.
5.
A robust 'reducing OAR dose optimization' is performed using 21 perturbed scenarios.
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In the present study, the algorithm was instantiated as follows:
To avoid any bias from proton beam angle selection, the beam configuration (step 1) of the DMR plans was copied from the reference proton plans. In the ROI selection (step 2), the CTVs and OARs related to patient-rated xerostomia, grade II-IV dysphagia and tube feeding dependence, and the spinal cord were included (see Table 1 ). Then the reference dose is set to Xref (step 3).
In the mimicking part (step 4), the DMR algorithm comprised DVH-based mimicking of Xref in the CTVs and OARs. This optimization aims to achieve a proton plan that has at least similar target coverage, also when uncertainty is considered, and at least similar OAR sparing as in the photon dose set in step 3. The DVH-based mimicking minimized the deviation between the DVHs of Xref and those of the proton plan being optimized. Plan robustness was only considered for the targets, and achieved by mimicking the nominal photon dose in each uncertainty scenario. Mathematically, the DVH-based mimicking utilizes the , where ܱ is the set of considered OARs, ܶ is the set of considered targets, ܵ is the set of considered scenarios, and ‫ݏ‬ denotes the nominal (planning) scenario. The parameter ‫ݒ‬ specifies where over-and underdosage should be penalized for targets. Per default, it was set to 0.5, but to include the dose gradient between low and high dose targets more accurately, it was set to 0.9 for targets where (D10 -D90) / D10 > 0.2 in Xref, which was the case for CTV2 in the studied patients. To illustrate, when the dose of the 
Analysis
For each proton plan (i.e. DMR and Pref plan), plan robustness was assessed by evaluating the treatment plan under 14 rigidly perturbed and equally distributed setup error scenarios. The collection of scenarios is sampled from a cube and projected on a sphere with radius M. In total, 8 vertices (x=±M/√3, y=±M/√3, z=±M/√3) and 6 faces (±M, 0,0); (0, ±M, 0); (0, 0, ±M) were used to derive the scenarios. For all scenarios the image was scaled by ±3% to account for range uncertainty. From the resulting 28 scenarios, a voxel-wise minimum dose was constructed from which the V95% of the CTV was derived and compared between the DMR and Pref plan. In addition, plans were evaluated in terms of (∆)NTCP values (see table 1 ) and target conformity (CI V95% ). The CI V95% was defined as the ratio between the absolute volume of the 95% isodose line and the V95% in the CTV.
Results
The DMR algorithm created clinically realistic robust treatment plans that were comparable to the The difference of V95% of the voxel-wise minimum dose between the DMR and the Pref plan was <0.05 in 35/40 and 37/40 of the cases for CTV1 and CTV2, respectively (figure 5a). The two outliers indicate the DMR plans that were optimized given an underdosed target DVH of the reference photon plans. The CI V95% of the voxel-wise minimum dose indicated that the DMR and Pref plan had, on average, similar target dose conformity for CTV1 (t-test using the 0.05 significance level: p = 0.16). On average (±1.96 SD), the CI V95% of the voxel-wise minimum dose distribution of CTV2 was 0.22 (±0.41) (p < 0.001) lower for the Pref plan than for the DMR plan, indicating slightly more conformal target coverage of the voxelwise minimum dose of the Pref plans (figure 5b).
Discussion
The dose 'mimicking and reducing' algorithm turned a photon dose distribution into a robust MFO proton plan comparable to the dosimetrist-optimized proton plan for 40 HNC patients. We simulated the modelbased approach within this cohort (i.e. the calculation of ∑∆NTCP values from the proton and photon dose distribution) and found that the DMR algorithm selected 80% of cases for the same treatment technique as when the reference proton plan was used. The DMR algorithm therefore can play a big role in automated planning and could also be used within the model-based approach pipeline to select patients for proton therapy.
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Dose mimicking has been presented previously and focussed on photon dose distributions only [14, 15] . A voxel and DVH-based mimicking algorithm was introduced by XXXX to automatically improve a given reference photon dose [15] . The author evaluated the algorithm in a phantom study and found that the dose of the reference plan could further reduce the OARs dose while maintaining target coverage.
McIntosh et al. applied a dose mimicking algorithm to a predicted dose distributions derived from dose distributions of a set of similar patients to automatically create a photon treatment plan for novel patients [14] . In this study we extended the dose mimicking algorithm from XXXX [15] toward photon to robust proton based dose mimicking. Also, the reducing OAR dose optimization part was extended to account for target robustness, taking multiple error scenarios into account.
We acknowledge that the automated planning algorithm did not include automated beam angle selection.
Therefore, we copied the beam configurations from the reference proton plan and automated beam angle selection will be subject of ongoing research. Moreover, to avoid inter-planner variability, all reference proton plans were created by one dosimetrist (XXXX). The reference photon plans were however extracted from the clinical database and generated by a variety of dosimetrists. This directly corresponds to the current clinical workflow for patient selection for proton therapy.
Improving the target coverage has not been investigated in this study. It can sometimes be the case that photon plans have inadequate target coverage, especially if the target is close to the patient surface (due to the photon build-up effect), or due to proximity of dose-limiting critical structures (e.g. the optic structures). With a photon reference dose, the DMR algorithm currently does not seek to improve on it even though it may be possible with PBS and since the DMR algorithm in this study used DVHmimicking, any target underdosage in the photon plan will carry through into the proton plan, just not necessarily in the same region. In these (few) cases, the dosimetrist-optimised proton plan had the more clinically acceptable dose distributions. It is therefore important that the reference photon plans have sufficient target coverage to begin with. If target coverage of the photon plans was compromised, one could utilize all slack that is gained from selecting protons to improve OARs (as has been done in this M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT study), or utilize some to also improve target coverage. Therefore, and also to study the full potential of the DMR algorithm, the DMR algorithm should be combined with e.g. a clinical goal-based normalization method for photon plans with underdosage. This was however outside the scope of the present study.
Future research will focus on the application of dose mimicking for adaptive treatments. The goal is to achieve at least the same target DVHs of the original plan onto the repeat CT. Moreover, to further improve the photon dose, the 'reducing' function can be applied onto the photon dose distribution before patient treatment selection is performed. This would potentially reduce the NTCP values derived from the photon plan and consequently lead to a fairer selection of patients for proton therapy.
In conclusion, the DMR algorithm automatically optimized a robust proton plan using a photon reference dose. We developed a fully automated tool to select head and neck cancer patients for proton therapy by combining the DMR algorithm with the model-based approach. 
